New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 8, 2012
10:30 EDTRVBD, JNPR, CY, TECH, NEON, HSKA, CSCO, SD, LGND, FFIV, CFNLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Cardinal Financial (CFNL) initiated with a Buy at Janney Capital... Cisco (CSCO) initiated with a Buy at Citigroup... Cypress Semiconductor (CY) initiated with a Sell at Cantor... F5 Networks (FFIV) initiated with a Buy at Citigroup... Heska (HSKA) initiated with a Buy at C.K. Cooper... Juniper (JNPR) initiated with a Buy at Citigroup... Ligand Pharmaceuticals (LGND) initiated with a Buy at Cantor... Neonode (NEON) initiated with a Buy at Cantor... Riverbed (RVBD) initiated with a Buy at Citigroup... SandRidge Energy (SD) initiated with an Outperform at RBC Capital... Techne (TECH) initiated with a Market Perform at William Blair.
News For CFNL;CSCO;CY;FFIV;HSKA;JNPR;LGND;NEON;RVBD;SD;TECH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
19:22 EDTCSCOAmazon, Google, Netflix, others establish alliance to develop new media format
Amazon (AMZN), Cisco (CSCO), Google (GOOG), Intel (INTC), Microsoft (MSFT), Mozilla and Netflix (NFLX) announced the formation of the Alliance for Open Media, "an open-source project that will develop next-generation media formats, codecs and technologies in the public interest." The alliance added that it is committing its collective technology and expertise to meet "growing Internet demand for top-quality video, audio, imagery and streaming across devices of all kinds." The alliance's initial focus is to deliver a next-generation video format that is interoperable and open; optimized for the web; scalable to any modern device; optimized for hardware; capable of highest-quality and real-time video delivery; and flexible for both commercial and non-commercial content, including user-generated content. The initial project will create a new, open royalty-free video codec specification based on the contributions of members, said the group. Additional information on the alliance will be available later this year. Reference Link
11:28 EDTNEONNeonode signs multi-year license agreement with leading Japanese printer OEM
Subscribe for More Information
10:59 EDTFFIVCyberArk bucks downward market trend after Piper upgrade
The shares of Israeli cybersecurity company CyberArk (CYBR) are flat despite the large decline in the broader market after research firm Piper Jaffray upgraded the stock to Buy from Hold. The stock's decline has created an attractive entry point, as companies are becoming more interested in the type of products CyberArk offers, Piper analyst Andrew Nowinski contended. WHAT'S NEW: After conducting extensive checks, Nowinski believes that companies are becoming more interested in Privileged Account Management, the area in which CyberArk specializes. Enterprises are focusing on this area more intently because they realize they need to spend more on protecting their most critical assets within firewalls, the analyst stated. As a result of this trend, CyberArk's market share gains could accelerate, Nowinski believes. Moreover, the company is one of the few cybersecurity companies capable of generating 40%+ revenue growth and 20%+ operating margins, the analyst stated. Additionally, the company's 2016 free cash flow should come in nearly triple analysts' consensus 2016 estimate, said Nowinski, who set a $70 price target and Overweight rating on the shares. OTHERS TO WATCH: Other publicly traded IT security companies include Barracuda (CUDA), Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC). PRICE ACTION: In morning trading, CyberArk was little changed at $51 per share.
10:56 EDTCSCO, JNPRRBC Capital to hold a bus tour
Subscribe for More Information
09:34 EDTCSCOActive equity options trading on open
Subscribe for More Information
07:49 EDTCSCO, FFIV, JNPRData networking shares should be bought on weakness, says Bernstein
Bernstein says that Cisco (CSCO), Juniper (JNPR), and F5 Networks (FFIV) are down almost 10% recently, although they have "limited exposure" to China, according to the firm. Additionally, even in the face of wider macro economic weakness, Cisco "would still be protected by a positive product cycle momentum," while Juniper would be shielded by "the late cycle nature" of the spending trends of its service provider customers, according to the firm. Bernstein keeps Outperform ratings on all the stocks named.
August 31, 2015
14:05 EDTCSCOApple, Cisco announce partnership for 'fast lane' for iOS enterprise users
Subscribe for More Information
11:03 EDTCSCOEricsson signs OSSii license agreements with Cisco and Tektronix
Subscribe for More Information
08:14 EDTCYPacific Crest identifies favorite semiconductor stocks
Pacific crest says that the semiconductor sector is being stymied by decade-high inventory levels and uncertain demand. In the current environment, the firm expects semiconductor stocks with high dividend yields and ongoing cost-reduction initiatives to outperform. It identifies Maxim Integrated (MXIM), Cypress Semiconductor (CY), Applied Materials (AMAT), and KLA-Tencor (KLAC) as its favorite names in the sector. It keeps Overweight ratings on all the stocks named.
August 28, 2015
16:18 EDTCSCOCisco CEO Charles Robbins adopts 10b5-1 trading plan
Subscribe for More Information
07:17 EDTFFIV, CSCO, JNPRCoomunication tech stock drop likely a buying opportunity, says Wells Fargo
Subscribe for More Information
August 25, 2015
09:35 EDTCSCOActive equity options trading on open
Subscribe for More Information
August 24, 2015
14:21 EDTFFIVJMP Securities says pullback in Palo Alto a buying opportunity
Subscribe for More Information
13:15 EDTLGNDFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
August 21, 2015
12:56 EDTTECHBio-Techne management to meet with William Blair
Subscribe for More Information
12:13 EDTJNPR, CSCOBrocade soars after Q3 results top estimates
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use